TruSight Oncology Product Family
TruSight Oncology Product Line
Comprehensive insights for precision medicine
Solutions to enable CGP using tissue or liquid biopsy samples
Diagnostic and research options to enable comprehensive genomic profiling (CGP)
The TruSight Oncology product family includes in vitro diagnostic (IVD) and clinical research solutions for solid tumor genomic analysis. Maximize insights by consolidating multiple iterative tests into one assay to assess DNA and RNA* biomarkers across more than 500 genes. Keep samples local and save time with testing in your own lab.
TruSight Oncology Comprehensive IVD solutions†
Integrated, sample to report IVD workflow enabling labs to interrogate both DNA and RNA content from FFPE tissue samples in ~5 days. Generate a comprehensive genomic profile (CGP) of a patient's tumor and improve chances of identifying a targeted therapy based on the latest clinical guidelines.
TruSight Oncology 500 clinical research solutions
Multiple assay configurations enable labs to perform in-house CGP using solid tumor tissue or circulating tumor DNA (ctDNA) in blood plasma for research. Similar content and workflow design across an innovative portfolio of products enable labs to consolidate platforms for more streamlined in-house operations.
*RNA variants are not included with TruSight Oncology 500 ctDNA v2 assays.
†For In Vitro Diagnostic Use. Not available in all regions and countries.
Rely on a global leader in NGS for CGP solutions
As an industry leader in NGS with 25+ years of innovation, you can rely on Illumina as your preferred provider of CGP solutions. As a single supplier with expertise across the entire workflow—from library preparation to sequencing through bioinformatics—Illumina can help you efficiently enable CGP in your lab. The Illumina portfolio provides a variety of options tailored to meet the needs of your institution.
Speak to a specialist
Contact an Illumina representative to learn more about the TruSight Oncology product line and find the right solutions for your needs.
References
- Soumerai TE, Donoghue MTA, Bandlamudi C, et al. Clinical utility of prospective molecular characterization in advanced endometrial cancer. Clin Cancer Res. 2018;24(23):5939-5947. doi:10.1158/1078-0432.CCR-18-0412.
- Gutierrez ME, Choi K, Lanman RB, et al. Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities. Clin Lung Cancer. 2017;18(6):651-659. doi:10.1016/j.cllc.2017.04.004.
- Singal G, Miller PG, Agarwala V, et al. Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database [published correction appears in JAMA. 2020 Feb 4;323(5):480]. JAMA. 2019;321(14):1391-1399. doi:10.1001/jama.2019.3241.
- Kato S, Kim KH, Lim HJ, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020;11(1):4965. Published 2020 Oct 2. doi:10.1038/s41467-020-18613-3.
- Rozenblum AB, Ilouze M, Dudnik E, et al. Clinical impact of hybrid capture-based next-generation sequencing on changes in treatment decisions in lung cancer. J Thorac Oncol. 2017;12(2):258-268. doi:10.1016/j.jtho.2016.10.021.
- Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients [published correction appears in Nat Med. 2017 Aug 4;23 (8):1004]. Nat Med. 2017;23(6):703-713. doi:10.1038/nm.4333.